Many newly defined tumour antigens are 'self ' proteins. Immunizing cancer patients against these antigens may be difficult due to tolerance. The HER-2/neu oncogenic protein is such a 'self ' tumour antigen. Rat neu is homologous with human HER-2/neu and provides a model system for studying vaccination strategies. Rats are tolerant to rat neu. Vaccination with this 'self ' protein elicits no detectable immune response. The current studies evaluated whether tolerance to rat neu can be circumvented by immunizing with the highly homologous foreign human HER-2/neu protein. Rats were immunized with human HER-2/neu intracellular domain (hICD) protein that is 92% homologous to rat neu ICD. Animals immunized with hICD developed significant antibody and T-cell responses that were specific for both human HER-2/neu and rat neu. Neu-specific antibodies were present in titres of greater than 15200 000. Analysis of the specificity of the antibody response using synthetic peptides demonstrated substantial reactivity to an epitope with 100% homology between rat and human protein. Significant T-cell responses (stimulation index>10) to hICD and rat neu protein (stimulation index>4) were detected. The T cells also responded to both human and rat ICD. The results imply that immunization with foreign proteins, which are highly homologous to 'self ' tumour antigens, may be an effective vaccine strategy for 'self ' tumour antigens.
INTRODUCTION
to neu in rats. Rat neu is a homologue for human HER-2/ neu, an overexpressed oncogenic growth factor receptor. A new generation of tumour antigens has been defined: self HER-2/neu is a proposed target for therapeutic cancer vaccines proteins.1,2 'Self ' proteins expressed by melanoma cells as in humans. It is overexpressed on a wide variety of adenocarcimelanocyte differentiation antigens, such as gp100, MAGE, nomas10-12 and is associated with a poor prognosis in several and MART-1, have been found to be immunogenic in humans subsets of patients. 13, 14 Rats are tolerant to rat neu.15,16 Rats who have melanoma.3-5 'Self ' proteins known to be involved vaccinated with either purified rat neu protein or rat neu in malignant transformation, such as HER-2/neu and c-myc, extracellular domain (ECD) expressed by vaccinia virus do have also been found to stimulate an immune response in not develop rat neu-specific immunity.15,16 Tolerance can be patients whose cancers express those proteins.6,7 Mutated circumvented in the rat, however, by immunization with cancer-specific proteins, such as p53 and ras, have segments peptides derived from the rat neu protein sequence. 16 This that are unique and thus cancer-specific. However, recent observation demonstrates cancer vaccines directed against studies suggest that the immunity directed against mutated 'self ' tumour antigens can be formulated to be effective in cancer-specific proteins is often targeted against the nongenerating immunity, but the use of peptides may be problemmutated or 'self ' epitopes.8,9 atic as they are thought of as weak immunogens and human Despite the presence of a detectable immune response to leucocyte antigen (HLA) restriction may limit usefulness. An 'self ' tumour antigens in some patients, immunological tolerideal vaccine strategy targeting a 'self ' tumour antigen would ance exists and represents a barrier to effectively vaccinating be one in which vigorous immunity could be elicited with one against tumour antigens. One model system in which immunizvaccine formulation for all patients. ation to a 'self ' tumour antigen has been evaluated is immunity
The current study evaluated whether immunization with a magnitude to impart an anti-tumour effect. Studies presented after the second immunization animals were assessed for immunological response. Sera, spleens and draining lymph here evaluate immunity to rat neu protein as a surrogate for studying immunity to human HER-2/neu protein. Results nodes were harvested from immunized animals. Experiments included four animals/experimental group. Data shown here showed that immunizing rats with human HER-2/neu intercellular domain (ICD), using a variety of different adjuvants, were derived from two separate immunization experiments for each group performed more than 2 months apart. results in the generation of high titre rat neu-specific antibodies and substantial rat neu-specific T-cell immunity. Antibody epitope mapping with synthetic peptides revealed responses to Cell lines Two cell lines were used as a source of neu proteins. SKBR3, a peptide with 100% homology between rat and human protein.
T-cell responses to both rat neu and human HER-2/neu were a human breast cancer cell line that is a marked overexpressor of HER-2/neu (American Type Culture Collection) was maindetected. Given that T-cells normally recognize peptides, the data implies that the T-cell responses are also directed to a tained in culture in 10% fetal bovine serum (FBS) (Gemini Bioproducts, Inc., Calabasas, CA) and RPMI. DHFRG8, an common epitope shared between human and rat ICD proteins.
NIH either a rat neu-specific antibody (c-neu-4, Oncogene Science) or a human HER-2/neu-specific antibody (520-C9, a kind gift Neu proteins Rat neu protein was purified using immunoaffinity column of Dr David Ring) at a concentration of 10 mg antibody per ml in carbonate buffer. After incubation, all wells were blocked purification techniques. Briefly, a lysate preparation of a rat neu overexpressing cell line, DHFRG8 (American Type with PBS and 1% bovine serum albumin (BSA) (Sigma Chemical Co., St. Louis, MO), 100 ml/well for 4 hr at room Culture Collection, Rockville, MD), was incubated overnight at 4°on a prepared immunoaffinity Affigel-10 column (BioRad, temperature. The plate was washed with PBS/0·5% Tween and protein was added. Rows of wells were coated with alternating Hercules, CA). To generate the lysate preparation 20×107 cells were used. 16 The Affigel-10 was coupled to a rat neu-PBS/1%BSA and DHFR-G8 lysate (rat neu) or SKBR3 lysate (human HER-2/neu) (108 cells/20 ml PBS ), 50 ml/well, overspecific antibody, 7.16.4 (kindly supplied by Dr Mark Greene). After incubation with lysate, the column was washed three night at 4°. After washing, the plate was incubated with rat sera at the varying dilutions in PBS/1% BSA and incubated times, twice with phosphate-buffered saline (PBS) and once with 1  NaCl. The rat neu protein was eluted with a buffer:
for 1 hr at room temperature. Sheep anti-rat immunoglobulin horseradish peroxidase (HRP) was added to the wells at a pH 2·5, 0·05  glycine, 0·15  NaCl, and 0·1% Triton-X and the eluent was immediately brought back to neutral pH with 155000 dilution in PBS/1%BSA and incubated for 45 min at room temperature (Amersham Co.). Following the final wash, 1  Tris-HCl. Pooled protein fractions were dialysed against PBS. After dialysis, the protein was concentrated by centrifu-TMB ( Kirkegaard and Perry Laboratories, Gaithersburg, MD) developing reagent was added. The optical density (OD) gation (Centricon-100, Amicon, Beverly, MA). The rat neu protein was sterile filtered (Nalgene, Rochester NY ). Protein was read at 450 nm. The OD of each serum dilution was calculated as the OD of the neu-coated wells minus the OD purity was verified by both protein staining and Western blot. 16 Purified protein was quantified (Bio-Rad Protein Kit).
of the PBS/1%BSA-coated wells. Antigen specificity was confirmed by analysing experimenRecombinant human and rat ICD proteins were kindly provided by Dr Kenneth Grabstein (Corixa Corp., Seattle, WA).
tal sera for antibody responses to ovalbumin in an ELISA. In these analyses, plates were incubated overnight at 4°with purified ovalbumin protein at 10 mg/ml concentration in carImmunization Rats were immunized recombinant human HER-2/neu intrabonate buffer alternating with rows of buffer alone. Antibody evaluation the proceeded as described above. cellular domain protein (hICD) (50 mg), or immunoaffinity column-purified rat neu protein (50 mg). Proteins were administered with either complete Freund's adjuvant (CFA; Sigma ELISA for peptide epitope analysis Ninety-six-well Immulon 4 plates (Dynatech Laboratories) ImmunoChemicals, St. Louis, MO) or murine granulocytemacrophage colony-stimulating factor (GM-CSF ) 5 mg were incubated overnight at 4°with 50 ml of a neu peptide solution at a concentration of 10 mg/ml diluted in PBS alternat-(Immunex Corp., Seattle, WA) as adjuvants. Control groups received adjuvant alone. Inoculations with GM-CSF were ing with rows of PBS/1%BSA. The peptides constructed were 15-18 amino acids in length and were derived from the amino given intradermally (i.d.) and inoculations with CFA were administered subcutaneously (s.q.). Animals underwent two acid sequence of the rat neu protein. Some peptides were located in areas of 100% homology between rat neu and immunizations each 14-16 days apart. Eighteen to 20 days human HER-2/neu. The peptide-coated plate was incubated of the rat neu protein that were 100% homologous with human HER-2/neu protein. The dominant response detected was to with rat sera diluted 1550 and 15100 for 1 hr at room temperature. Sheep anti-rat HRP was added to the wells at a an ICD peptide epitope, p932-946 (Fig. 2) . The amino acid sequence of this peptide is identical between rat and human. 155000 dilution in PBS/1%BSA and incubated for 45 min at room temperature. Following the final wash, the TMB developing reagent was added. The OD was read at 450 nm.
Immunization of rats with hICD elicits detectable T-cell The OD of each serum dilution was calculated as the OD of responses specific for both human and rat neu protein the peptide-coated wells minus the OD of the PBS/1%BSA-coated wells.
The conditions for circumventing T-cell tolerance may be more stringent than those needed to break B-cell tolerance.
T-cell proliferation assays
The key for a successful cancer vaccine targeting a 'self ' For analysis of neu protein-specific responses, immune spleen tumour antigen is the ability to generate significant T-cell cells were harvested by mechanical disruption and passage immunity. T-cell proliferative responses were evaluated in rats through wire mesh and washed. Two hundred thousand spleen immunized with hICD plus either GM-CSF or CFA. T-cell or 1×105 lymph node cells/well were plated into 96-well round responses to hICD protein were detected from lymph nodes bottom microtitre plates (Corning, Coring, NY ) with six draining the inoculation site (Fig. 3a) and spleen (Fig. 3b) . replicates per experimental group. The media used consisted T-cell responses to rat neu protein were also detected, although of EHAA 120 (Biofluids) with -glutamine, penicillin/streptoat a lower magnitude than the hICD response. There was no mycin, 2-mercaptoethanol, and 5% FBS. In initial experiments, evidence of response to an irrelevant protein, ovalbumin. cells were incubated with 1 mg/ml of the various proteins.
Animals immunized with rat neu protein with adjuvants or Subsequent experiments evaluated increasing concentrations adjuvants alone did not have a detectable T-cell response to of experimental proteins, recombinant human HER-2/neu either hICD or rat neu protein. ICD and recombinant rat neu ICD, ranging from 0·5 to Rats immunized with hICD developed significant prolifer-2·0 mg/ml. After 4 days, wells were pulsed with 1 mCi of ative responses to both human and rat ICD protein in a dose-[3H ]thymidine for 6-8 hr and counted. Data are expressed as dependent fashion (Fig. 4) . The magnitude of the T-cell a stimulation index (SI ) which is defined as the mean of the immune responses directed against rat or human neu protein experimental wells divided by the mean of the control wells was similar in rats immunized with hICD plus CFA at the (no antigen). Ovalbumin was used as a negative control antigen greatest concentration of antigen tested (2·0 mg). The magnifor proliferation in all assays at a 1 mg/ml concentration.
tude of the T-cell response against rat was less than the response to human in rats immunized with hICD plus GM-CSF at all concentrations. However, the possibility exists RESULTS that the responses would become more equivalent with Rats immunized with hICD develop high titre human and rat additional boosting.
neu-specific antibodies
Biopsies of skin, liver, lung, gastrointestinal tract, kidney and heart were obtained from immunized animals and evaluPrevious studies demonstrated that rats, immunized with rat neu protein, do not develop immune responses to rat neu. 15, 16 ated for histopathological evidence of autoimmunity. There was no evidence of autoimmune pathology in these tissues Animals are presumed tolerant to this 'self ' protein. For the current study rats were given a priming immunization and a which express basal levels of rat neu protein (data not shown). boost immunization with hICD with either GM-CSF or CFA as an adjuvant. All rats immunized with hICD developed DISCUSSION significant antibody responses specific for human HER-2/neu protein, with titres greater than 15200 000 (Fig. 1a) . By marked The HER-2/neu oncogenic protein is an overexpressed 'self ' protein implicated in the pathogenesis of many human maligcontrast, rats immunized with rat neu protein did not develop human neu-specific antibodies. Ovalbumin was used as a nancies. The HER-2/neu protein has been proposed as a target for immunotherapy, including cancer vaccines and monoclonal negative control protein. No sera tested was positive for antibodies to ova (data not shown).
antibody treatment.18 Some patients with HER-2/neuexpressing tumours have been found to have pre-existent Human HER-2/neu ICD is 92% homologous to rat neu ICD at the amino acid level. Analysis was performed to discern immunity directed against the protein.
19-21
Investigations in animal models demonstrate that a vigorous immune response whether the human HER-2/neu-specific antibodies were crossreactive with rat neu. Rats immunized with hICD with either directed against HER-2/neu can be beneficial in tumour eradication or protection.22 Neu transgenic mice treated with a GM-CSF or CFA as an adjuvant had high titre antibody responses specific for rat neu (Fig. 1b) . The magnitude of the murine HER-2/neu-specific antibody were protected from the development of neu-expressing mammary cancers. In addition, rat neu-specific antibody responses was nearly identical to that of the human HER-2/neu-specific response.
established tumour regressed with increasing doses of neuspecific antibody in animals with breast cancer.22 Human Human HER-2/neu and rat neu-specific antibodies, generated by immunizing with hICD, are specific for an intracellular clinical trials of infusion of HER-2/neu-specific antibodies resulted in regression of tumour in some patients with domain epitope with 100% homology between rat and human neu. Epitope mapping was done with a series of synthetic advanced stage breast cancer.23 Thus, inducing immunity in patients who have no pre-existing HER-2/neu-specific immune peptides (n=16) derived from the amino acid sequence of the rat neu protein. Both intracellular and extracellular peptides response, or boosting immunity in patients with an existent HER-2/neu-specific immune response is likely to have were included. Eight of the peptides were derived from regions therapeutic benefit. A major current therapeutic question is:
circumvented by immunizing rats with peptides derived from the rat neu protein. 16 We are currently addressing the question how best to immunize patients to this 'self ' tumour antigen to elicit vigorous HER-2/neu specific immunity?
of the efficacy of peptide-based vaccines in human vaccine trials. Responses to HER-2/neu protein are detectable in only a minority of patients with HER-2/neu-positive cancers. Eliciting
While effective, peptide immunization may be difficult to apply to an outbred human population with disparate major a vigorous immune response to the HER-2/neu protein in such patients may be difficult due to immunological tolerance histocompatibility complex (MHC ) backgrounds. Despite the efficacy of peptide vaccination in the rat model, an ideal directed against this 'self ' protein. The rat offers a good model for the evaluation of immunological strategies directed against vaccine strategy targeting a 'self ' tumour antigen would be one in which the vaccine formulation would be effective in all the neu protein. Rats have been shown to be tolerant to rat neu. 15 ,16 Recent studies demonstrate that tolerance can be patients, such as by use of protein with multiple potential Figure 2 . Human HER-2 and rat neu-specific antibodies, generated by immunizing with hICD, are specific for an intracellular domain epitope with 100% homology between rat and human neu. Sera derived from animals in each experimental group were evaluated in ELISA for antibody response to 16 peptides derived from the amino acid sequence of the rat neu protein structure. Eight of the 16 peptides were derived from sections of the rat neu protein that were 100% homologous with human neu. These peptides are underlined. This figure represents data collected from two separate experiments with eight experimental animals in each group. Results are depicted as the mean and standard deviation of the antibody response of each experimental group at a sera dilution of 15100.
epitopes, rather than peptide with a single epitope appropriate derived from the rat neu protein sequence, demonstrated a substantial antibody response directed to an epitope with 100% for only a small family of MHC molecules. Vaccination with molecular mimic proteins has been an effective strategy in homology between rat and human neu protein.
Vaccine strategies that elicit significant numbers of 'self '-generating immunity to 'self ' particularly in the development of anti-fertility vaccines. In particular, vaccinating animals reactive B cells may lead to the generation of 'self '-reactive T cells. The presence of B cells specific for 'self ' protein can with purified zona pellucida protein derived from a different species can result in the generation of high titre 'self ' zona result in the circumvention of T-cell tolerance to the same protein.26 Antibody to 'self ' protein can bind to and serve to pellucida antibodies that render the animal infertile.24,25 The studies described herein addressed whether a similar strategy concentrate the 'self ' protein in antigen-presenting cells and in this fashion, stimulate T-cells specific for 'self ' in addition could be applied to 'self ' tumour antigens for the purpose of developing human cancer vaccines.
to foreign protein epitopes. Accordingly, rats immunized with hICD developed T-cell responses specific for both rat and Rats immunized with human ICD developed antibody titres greater than 15200 000 specific for hICD. Of note, the human neu proteins. Rats immunized with rat neu protein did not generate rat-specific T-cell immunity indicating tolerance human neu-specific antibodies were cross-reactive with rat neu protein. A similarly vigorous antibody response to 'self ' neu to neu was present at the level of the T-cell. Although the magnitude of the T-cell response was greater for the foreign protein could be detected. By contrast, as previously reported, rats immunized with rat neu protein did not develop antibody protein, the response to self protein was substantial. There are several possible explanations for the differences responses.15,16 An expected result might have been vigorous antibody response to human protein with a detectable, but noted between the magnitude of the T-cell responses to hICD as compared to rat neu protein. First, a portion of responding substantially lower titre antibody response to rat neu protein. This scenario would occur if immunity was directed primarily T-cell population might recognize heterologous epitopes only and be specific for ICD only. Another possibility is that the to foreign epitopes in the human HER-2/neu protein.
Evaluation of the antibody response, using peptide epitopes ECD portion of the protein, present in the intact rat neu, has a suppressive effect. There may be a difference in the ability affinities for recognition of human neu versus rat neu peptide epitopes. Higher concentrations of rat ICD are required to to generate immunity to the ICD or the ECD portion of the neu protein. Theoretically, tolerance is most stringent for the achieve a similar stimulation index seen at lower concentrations of hICD (Fig. 4) . self proteins most available to the immune system. By virtue of a normal intracellular location, the ICD is more likely to
The field of tumour immunology has been stimulated by observations of existent immune reactivity to 'self ' proteins in be sequestered from the immune system and, therefore, less likely to have elicited a prior stringent tolerizing response. The some patients. However, in the majority of patients, the reactivity is non-existent or of low magnitude. Investigations ECD is located extracellularly, is shed and may be more available for prior immune recognition. Thus, the ECD would in many tumour systems in animal models show that a vigorous immune response is required for tumour eradication.27 Cancer be more likely to elicit a tolerizing response. It is possible that tolerance to the ECD exists and that presentation of ECD vaccines attempting to boost or generate immunity in vivo to 'self ' tumour antigens must deal with the role tolerance plays epitopes results in a blunting of the ICD-specific response. Finally, populations of responding cells may have differing in hampering the immune response. The current studies give 
